EP0923736A1 - Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique - Google Patents

Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique

Info

Publication number
EP0923736A1
EP0923736A1 EP97930402A EP97930402A EP0923736A1 EP 0923736 A1 EP0923736 A1 EP 0923736A1 EP 97930402 A EP97930402 A EP 97930402A EP 97930402 A EP97930402 A EP 97930402A EP 0923736 A1 EP0923736 A1 EP 0923736A1
Authority
EP
European Patent Office
Prior art keywords
carrier material
affinity
carrying
solid phase
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97930402A
Other languages
German (de)
English (en)
Inventor
Christoph ABION Beteiligungs ERHARDT
Peter Abion Beteiligungs MIETHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abion Beteiligungs und Verwaltungs GmbH
Original Assignee
Abion Beteiligungs und Verwaltungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abion Beteiligungs und Verwaltungs GmbH filed Critical Abion Beteiligungs und Verwaltungs GmbH
Publication of EP0923736A1 publication Critical patent/EP0923736A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin

Definitions

  • the present invention relates to a use according to claim 1.
  • Analytical methods which use methods of genetic engineering or other methods based on genes, such as are described, for example, in “Profitmg from Gene-based Diagnostics”, CTB International Publishing Inc., Maplewood 1996, ISBN 1-887566-04-x , such as Amplification reactions by means of molecular biological methods, such as, for example, the polymerase chain reaction (PCR) or hybridization methods such as, for example, the "branched DNA” system with detection amplification by means of multiply branched and labeled connections of the complementary DNA, have become important analytical tools.
  • the amplification methods are known for their sensitivity. For example, PCR is one of the most sensitive analytical methods and has considerable potential for future analytical systems.
  • Another disadvantage of the amplification reactions currently used is that they are disturbed by inhibitors. For example, in analytical tests from whole blood, a polymerase chain reaction is not possible without switching off the inhibitors.
  • the technical problem on which the invention is based is to avoid the above-mentioned disadvantages of the prior art and to enable direct virus detection even with very low titers of the free virus. Furthermore, inhibitors of the amplification reactions are to be switched off.
  • PCT / EP 97/00405 relates to a carrier material in the form of a shaped body, loose fillings of the sorbent material in particle form, in the form of a gel or as a dispersion for the preparation of samples which are examined using genetic engineering analysis methods, the carrier material carries at least one component for carrying out solid phase assays and is permeable to a fluid.
  • the carrier material is characterized in that it has an average pore diameter of 0.1 to 100 ⁇ m, no or a very low non-specific sorption capacity for affective has materials.
  • the carrier material is standardized by the proviso that the component on a specific unit volume of the carrier material for carrying out solid phase assays (affectionate material) has its complementary component with the single homogeneous flow of a certain amount of a dilute solution of the complementary component in one certain concentration of this complementary amount binds specifically in such an amount that fluctuates between several statistically relevant loading processes by a loading value ⁇ 40% and that the bound amount during several subsequent flow-through processes of suitable liquids on the carrier material, such as blockages of specific or non-specific ones Adsorption sites, washing of the carrier material loaded with the component for carrying out solid phase assays, and addition of affinity-reactive materials, remain constant in the range mentioned.
  • the use according to the invention now enables a simple machine-readable detection system, for example for PCR results, to be developed with, in particular, hydrophilic carrier materials in combination with DNA probes and sensitive dyes, as are described in particular in WO 97/19354.
  • the carrier material which can be used according to the invention is operated, for example, as an analytical enrichment column with high specificity, selectivity and high degree of enrichment.
  • a Sample for example from a larger sample quantity than is directly required for the PCR or from pooled samples, to enrich a sought-after agent, such as a virus, and nucleic acids not searched for by a washing step, as well as substances containing DNA / RNA or other interfering substances such as, for example Remove inhibitors.
  • a sought-after agent such as a virus
  • nucleic acids not searched for by a washing step as well as substances containing DNA / RNA or other interfering substances such as, for example Remove inhibitors.
  • different agents can also be enriched from a (larger) sample without additional sampling and, if necessary, separately amplified by separating the layers before the elution.
  • the elution of the corresponding devices in which the support materials according to the invention are arranged is preferably carried out directly with the start buffer of the respective method, e.g. the polymerase chain reaction in a corresponding reaction vessel.
  • This pre-cleaning immunoaffinity treatment increases the selectivity of amplification reactions, in particular the PCR test, so that the high sensitivity of this method can be exploited in an ideal way.
  • This variant also ensures band amplification of the amplified DNA in corresponding electrophoresis gels or a deepening of color in the detection in devices according to the invention, or even enables reliable detection in the extremely low concentration range, as the exemplary embodiment shows.
  • the measuring range for standardized PCR amplification is defi ned by at least two orders of magnitude shifted to lower concentrations (standardized Sampling) .
  • the device according to the invention for sample preparation (enrichment and / or purification) and for subsequent detection (qualitative and / or quantitative) supplements the actual PCR, it is used, for example, when using branched DNA ("branched DNA” ) is used as the exclusive device, ie the virus sought (or the DNA sought if required) is enriched in a device according to the invention. After that, the detection is carried out either directly with a branched multi-marked Affinity partner, or the virus is eluted and digested and accordingly bound and detected in a second device according to the invention.
  • branched DNA branched DNA
  • Inhibitors of the amplification reaction are also removed by the use of the sorbents according to the invention.
  • a device that can be used according to the invention with the carrier materials that can be used according to the invention can, after amplification of the samples, also be used to quantify the corresponding nucleic acid, e.g. DNA.
  • the carrier material is used for the quantification, which in the first step binds the nucleic acid (DNA) generated in the amplification reaction (PCR).
  • the quantitative detection with highly sensitive dyes, which are used, for example, is then carried out using DNA probes, preferably biotinylated DNA probes. coupled with streptavidin.
  • the carrier material which can be used according to the invention for carrying out a solid phase assay can be in the form of a shaped body, loose fillings, a sorbent material in particle form, which is explained in more detail in PCT / EP 97/00405, in the form of a gel or as a dispersion.
  • the carrier material carries at least one component for carrying out solid phase assays and is also permeable to a fluid.
  • the carrier material has an average pore diameter of 0.1 to 100 ⁇ m, the pore in the case of corresponding materials being understood to mean the interspace between particulate particles and not the porosity of the surface of the corresponding particle.
  • the carrier material has no or only very low non-specific sorption ability for affinity materials. In contrast, it has a high affinity for certain components which are complementary to the affinity material arranged on the carrier material.
  • the carrier material according to the invention is standardized by the proviso that the component located on a certain bulk volume of the carrier material for carrying out solid phase assays (affinity material) is its complementary component with a single homogeneous flow of a certain amount of a certain solution of this complementary component in a certain concentration of this complementary component, specifically in such an amount that it fluctuates between several statistically relevant loading processes by an average loading value of at most + 40%.
  • the fluctuation is in particular not more than ⁇ 30%, preferably + 20% and in particular preferably not more than + 10%.
  • the bound amount remains constant in the mentioned range even in the case of several subsequent flow-through processes of suitable other liquids on the carrier material. Again, eluting liquids are not suitable.
  • Blocking steps of specific or unspecific adsorption sites in particular washing of the carrier material loaded with the component for carrying out solid phase assays, further affinity binding steps for marking and / or reinforcement, etc. are particularly suitable as further flow-through processes.
  • the carrier material according to the invention is advantageous because it can be manufactured relatively easily, without great expenditure of time and equipment, and in particular also easily by the user himself, from easily available components, namely, on the one hand, from the sorbent according to PCT / EP 97 / 00405 and the affinity material or materials used for Carrying out a solid phase assay are required as well as a flow-through vessel.
  • buffer solutions can also be offered, which can be used to load the carrier material.
  • the carrier material which can be used according to the invention is obtainable by loading the sorption material according to PCT / EP 97/00405 in a single flow through a certain amount of at least one solution with a certain concentration of at least one component for carrying out solid phase assays. It is further preferred that the carrier material carries at least one component for carrying out solid phase assays of the carrier material and that free unspecific sorption sites of the carrier material are blocked.
  • the carrier material which can be used according to the invention in particular carries an affinity material composed of molecules, groups of molecules or particles with affine properties for other substances.
  • the affinity material is particularly selected from the group of enzymes, substrates which interact with enzymes, antibodies, antigens, such as high-molecular substances or pollen or other allergens, haptens, biotin or streptavidin, nucleic acids from RNA or DNA Type, especially those that can be hybridized with other nucleic acids, receptor or ligands of a receptor, viruses, bacteria, cells, cell organs, blood cells, particles, such as colloidal particles of metals, metal oxides, polymers or combinations of the affinity materials mentioned.
  • the carrier material according to the invention can also be produced from the carrier material according to the invention by bringing the analyte (s) into contact with the carrier material without prior modification with non-specific material.
  • the device for use according to the invention is preferably a hollow body, in the lumen of which one or more of the carrier materials which can be used according to the invention are arranged are. If one or more carrier materials with different components for solid phase assays are arranged in the device, this is done in such a way that a homogeneous flow through the hollow body, in particular the areas with carrier material, is ensured. In particular, there should be no edge effects or other areas in which the flow is faster or slower than at other points. This property is essentially determined by the standardization of the carrier material. In addition, an exact fit of the sorption or carrier material with the most exact geometric shape possible (cylinder with cross section corresponding to the cross section of the flow-through vessel) is important according to the invention.
  • the sorption and / or carrier materials can be fixed in the form of loose fillings or gels by means of devices arranged in the lumen of the hollow body. These devices preferably have a homogeneous flow behavior for a fluid, in particular solutions with analytes, furthermore the devices have in particular only a low own or preferably no unspecific sorption capacity for affinity materials.
  • a process for the production of the support material which can be used according to the invention is based on the fact that the support material which can be used according to the invention is treated with one or more affinity materials, in each case essentially in solution with a specific concentration in a certain amount of liquid. This can be done on the one hand in a batch process, on the other hand and preferably, however, in a homogeneous flow in a hollow body with an inlet and outlet opening, in which the carrier material is arranged.
  • the latter procedure has the advantage that a standardized carrier material with a high, uniform loading in relation to the concentration used is obtained in a very short time and without any outlay on equipment.
  • a comparable loading in the batch process takes a very long time, since initially only outer areas of the sorbent are loaded in the difference for the flow-through method, in which the entire material, ie also the inner surface, comes into contact with the affinity material quickly.
  • the latter procedure enables the carrier material to be produced directly by the user in a simple manner.
  • the corresponding carrier material can also be produced in larger batches and then in devices for carrying out solid phase assays.
  • free sorption points of the carrier material are blocked with corresponding substances which are inert in the solid phase assay to be carried out. If necessary, the carrier material is washed one or more times.
  • the carrier material and pure preliminary product can be found in PCT / EP 97/00405.
  • the homogeneous flow relevant according to the invention is correlated with a uniform pore structure, particularly with regard to the adsorbing inner surface, over the surface of the support materials, but also over their cross section, i.e. in the direction of flow.
  • a uniform pore structure particularly with regard to the adsorbing inner surface, over the surface of the support materials, but also over their cross section, i.e. in the direction of flow.
  • Such a symmetrical, homogeneous pore structure is advantageous.
  • HBV hepatitis B virus
  • HDV hepatitis D virus
  • Round frit made of polyethylene, 5 mm in diameter, 5 mm in height, precise in shape for the cross section of a flow-through vessel, punched out of filter plates which were produced by sintering from polyethylene powder with a narrow particle size distribution by sieving (particle size below 250 ⁇ m); Nominal pore size 50 ⁇ m (bubble point),
  • Pore size distribution with Coulter porometer from 5.492 to 138.6 ⁇ m, average pore size 13.64 ⁇ m, 1.063% of the pore number over 27.5 ⁇ m, 15.45% over 15.92 ⁇ m (Abion GmbH, Irishlich, Germany); round, tapered, empty flow-through vessels in the lower part according to DE 4126436 AI, diameter 5 mm, capacity for sample solutions via a 5 mm high frit attached to the upper end of the conical part, approx. 0.8 ml (from Abion GmbH , Irishlich, Germany);
  • the volume of the carrier material was 80 ⁇ l
  • HBV-IgG bound to the carrier material was 40 ⁇ g.
  • a conventional PCR for HBV-DNA and HDV-RNA is described below in comparison with a treatment on the carrier material to be used according to the invention.
  • the reaction mixture contained 10 ul of a PCR buffer (105 mM Tris HCl, pH 8.8, 81.5 mM ammonium sulfate, 30 mM magnesium dichloride, 0.5% nonidet P40 - Tween 20), 4 ul of each dNTP mixture, 5 units Taq Polymerase (Biomaster, Moscow), each 200 pM of the primer were added.
  • the primers were selected using the PRIMER MASTER 1.0 computer program and flanked the surface gene region of 359 bp.
  • the PCR was carried out in 30 cycles using the following temperature profile: 93 ° C, 1 min, 58 ° C, 1 min, 72 ° C, 1.2 min.
  • the amplified fragments were analyzed in agarose gels and stained with ethidium bromide.
  • 100 ⁇ l of serum were diluted with an equal volume of a w-500 buffer containing 50 mM Tris HCl, pH 8.0, 150 mM sodium chloride, 0.1% sodium azide, 0.5% Tween 20 and on a column described above loaded with the carrier material to be used according to the invention.
  • the virus parmules were washed with 100 ⁇ l of a denaturing solution containing 50 mM Tris HCl, pH 8.0, 1% SDS, 25 mM EDTA, eluted.
  • the eluate was collected in an Eppendorf tube and incubated 30 mm at a temperature of 60 ° C. Thereafter, it was precipitated with ethanol.
  • the pellet was collected by centrifugation, washed twice with 70% ethanol and dissolved in 100 ul water.
  • the HBV-DNA was then amplified by means of PCR. 30 ⁇ l of the DNA solution were amplified in 50 ⁇ l PCR reaction mixture.
  • Serum RNA was obtained by acidic guadinium thiocyanate phenol / chloroform extraction. The following reagents were successively added to 100 ⁇ l of the serum
  • the suspension obtained was shaken vigorously and cooled on ice for 5 mm.
  • the sample was centrifuged at 10,000 g for 20 min at 4 ° C.
  • the aqueous phase was extracted with an equal volume of chloroform and the aqueous phase obtained was precipitated with a volume of isopropanol.
  • the RNA pellet was dissolved in 50 ⁇ l water and treated with diethyl pyrocarbonate.
  • RNA obtained was added to 17 ul reverse transcription (RT) mixture.
  • This mixture contained 4 ⁇ l of a 5 ⁇ RT buffer (250 mM Tris HCl, pH 8.3, 250 mM potassium chloride, 50 mM magnesium dichloride, 50 mM DTT, 2.5 mM spermidine), 2 ⁇ l 10 mM per deNTP, 1 ⁇ l (100 ng) of random hexanucleotides, 0.5 ⁇ l (20 units) HPRI (from Promega) and 9.5 ul water.
  • the mixture was heated at 94 ° C for 3 minutes and then cooled on ice. After denaturation, 1 ul (10 units) AMV reverse transcriptase (Promega) and 0.5 ul (20 units) HPRI were added.
  • the cDNA synthesis was carried out at 37 ° C for 45 min.
  • 10 ul of the cDNA were amplified in 50 ul of the PCR reaction mixture containing 10 ml of a 5-fold PCR buffer (150 mM Tris HCl, pH 8.8, 81.5 mM ammonium sulfate, 0.5% nonidet P40 - Tween 20), 4 ⁇ l of 10 mM of the respective dNTP, 1 ⁇ l (5 units) of Taq polymerase (Biomaster), 1 ⁇ l (200 pM) of each backward or forward primer contained.
  • the PCR was carried out in 40 cycles, the following temperature profile being maintained: 94 ° C., 1 minute, 57 ° C., 1 minute, 72 ° C., 1.2 minutes.
  • the amplified fragments were analyzed in an agarose gel and stained with ethidium bromide.
  • 100 ⁇ l of the serum was diluted with an equal volume of 150 mM sodium chloride and loaded onto the column described above. After washing the column with 500 ⁇ l of a solution of 150 mM sodium chloride, the virus particles were eluted with 200 ⁇ l of denaturing solution containing 3.2 M guanidium thiocyanate, 20 mM sodium citrate, pH 7.0, 0.4% sarcosyl. The eluate was collected in Eppendorf tubes, mixed well with 2 mM sodium acetate, pH 4, 0 and 2 ⁇ l 2-mercaptoethanol and then precipitated with ethanol.
  • RNA pellet After centrifuging the RNA pellet, it was dissolved in 20 ⁇ l of water and 10 ⁇ l of the RNA solution was used in the reverse transcription reaction (RT reaction).
  • RT reaction reverse transcription reaction
  • the RT reaction and the PCR were carried out as described above.
  • the examples show the following result:
  • the DNA was extracted from 10 HBV PCR positive and 5 HBV PCR negative subjects according to the standard method of DNA isolation. These were used with the carrier material to be used according to the invention in corresponding columns. The amplification of these DNA samples showed the presence of specific fragments in a total of 10 cases. Amplification of the DNA samples, which had been isolated according to the standard method, gave no specific fragments.
  • HBV-DNA and HDV-RNA that have been extracted using the carrier material with purified virus particles to be used according to the invention can be used for PCR tests in amounts equivalent to 100 ⁇ l. In this case, an increase in the synthesis efficiency is observed.
  • RNA samples from anti-HD positive and HDV RNA negative patients were examined.
  • 500 ⁇ l of each serum were applied to columns which contained the carrier material to be used according to the invention, RNA was collected from viral particles and extracted using the phenol-chloroform method, followed by ethanol precipitation. The total amount of RNA isolated was subjected to the reverse transcript reaction and half of the RT Mixtures used in the PCR. The sera were tested in parallel in the standard RT-PCR assay. Specific HDV genome fragments were observed in three samples which were treated using the support materials used in columns according to the invention, whereas no specific fragments could be determined in samples according to the standard assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Utilisation d'un matériau support, sous forme d'un corps moulé, de charge lâches du matériau de sorption sous forme de particules, d'un gel ou d'une dispersion, pour la préparation et la détection d'échantillons à analyser suivant des procédés d'analyse de génie génétique. Le matériau support porte au moins un composant pour l'exécution de l'essai en phase solide et est perméable à un fluide; il présente un diamètre moyen de pores de 0,1 à 100 νm; il ne présente aucune ou seulement une très faible capacité de sorption non spécifique pour des matériaux d'affinité; le matériau support est normalisé de telle façon que le composant se trouvant dans un volume unitaire déterminé du matériau pour l'exécution des essais en phase solide (matériau d'affinité) fixe son composant complémentaire lors du passage homogène en une seule fois d'une quantité déterminée d'une solution diluée du composant complémentaire à une concentration déterminée en ce composant, spécifiquement en des quantités pouvant varier, entre plusieurs opérations de charge statistiquement adéquates, autour de valeurs de charge de ± 40 %. La quantité fixée demeure constante, dans la plage précitée, pour une pluralité de passages subséquents de fluides appropriés sur le matériau support, tels que blocages de zones d'adsorption spécifiques ou non spécifiques, lavages du matériau support chargé du composant pour effectuer les essais en phase solide, ainsi qu'amenée des matériaux à réaction d'affinité.
EP97930402A 1996-06-25 1997-06-25 Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique Withdrawn EP0923736A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19625211 1996-06-25
DE19625211 1996-06-25
PCT/EP1997/003332 WO1997049992A1 (fr) 1996-06-25 1997-06-25 Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique

Publications (1)

Publication Number Publication Date
EP0923736A1 true EP0923736A1 (fr) 1999-06-23

Family

ID=7797838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97930402A Withdrawn EP0923736A1 (fr) 1996-06-25 1997-06-25 Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique

Country Status (4)

Country Link
EP (1) EP0923736A1 (fr)
JP (1) JP2000514644A (fr)
AU (2) AU3344597A (fr)
WO (2) WO1997049992A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053553C2 (de) * 2000-10-28 2002-09-19 Bag Biolog Analysensystem Gmbh Vorrichtung zum Nachweis und zum Anreichern von Biomolekülen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126436A1 (de) * 1990-09-17 1992-03-19 Abion Ohg Einwegreaktionsgefaess fuer die festphasenimmunanalytik und verfahren zur messung von ueber immunreaktionen bestimmbaren komponenten
WO1995019569A1 (fr) * 1994-01-13 1995-07-20 Abion Beteiligungs- Und Verwaltungsgesellschaft Mbh Colonnes de reaction destinees a des mesures multiples et simultanees et procede
JP2000507347A (ja) * 1996-01-30 2000-06-13 アヴィオン ベタイリグンクス― ウント フェルヴァルトゥンクス―ゲゼルシャフト ミットベシュレンクテルハフツング 固相アッセイ用の流動充填可能な支持体材料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9749992A1 *

Also Published As

Publication number Publication date
AU3436897A (en) 1998-01-14
WO1997049992A1 (fr) 1997-12-31
AU3344597A (en) 1998-01-14
JP2000514644A (ja) 2000-11-07
WO1997049991A1 (fr) 1997-12-31

Similar Documents

Publication Publication Date Title
AT395434B (de) Verbessertes verfahren zum nachweis von nucleinsaeuren und reagenzienkombination und besteck zu seiner durchfuehrung
DE2522086C2 (de) Reagenz zum Abtrennen und Bestimmen von in biologischen Fluiden vorhandenen AK:Ag-Komplexen
EP1121460A1 (fr) Procedes et moyens pour l'isolement et la purification d'acides nucleiques sur des surfaces
DE102006050871B4 (de) Integriertes mikrofluidisches Bauteil zum Aufreinigen von Analytmolekülen sowie Verfahren zum Aufreinigen
DE3717211A1 (de) Vorrichtung und verfahren zur trennung und reinigung von molekuelen
DE102017204267B4 (de) Verfahren zur anreicherung von zellen aus einer probe und der nachfolgenden nukleinsäureisolierung aus diesen zellen
EP1257364A2 (fr) Recipient pour l'analyse d'acide nucleique
EP1436609B1 (fr) Procede d'extraction microfluidique
EP2068143A1 (fr) Manipulation de microparticules magnétiques dans un système de liquide à haute pression et processus d'extraction
DE19736366A1 (de) Verfahren zur Isolierung von anionischen organischen Verbindungen aus wäßrigen Systemen mit kationischen Polymernanopartikeln
DE4208732C2 (de) Einwegreaktionsgefäß für die Festphasenimmunanalytik und Verfahren zur Messung von über Immunreaktionen bestimmbaren Komponenten
WO2015188994A1 (fr) Procédé d'enrichissement et/ou de purification d'acides nucléiques
EP1262759B1 (fr) Microplaque de traitement d'échantillons
EP0923736A1 (fr) Utilisation d'un materiau support pour la preparation et la detection d'echantillons dans un procede d'analyse en genie genetique
DE69914804T2 (de) Methode zur trennung von nukleinsäuren in populationen
EP2411811B1 (fr) Superposition de phases pour la séparation de particules
EP1103622B1 (fr) Détection d'acides nucléiques pour des espèces spécifiques utilisant un élément d'analyse
EP3610013B1 (fr) Désorption d'acides nucléiques
DE102004045332B3 (de) Verfahren zur Isolierung und Trennung von einzel- und doppelsträngigen Nucleinsäuren aus einer diese Nucleinsäuren enthaltenden Probe sowie Trennsäule zur Durchführung dieses Verfahrens
EP0873427B8 (fr) Procede de detection et de quantification de molecules d'acide nucleique
DE102008050588A1 (de) Monolithische Säule mit immobilisiertem monomeren Avidin zur Anreicherung und Identifizierung biotinylierter Spezies
EP1880017B1 (fr) Procédé pour produire des ligands, ligands et kit de test
DE102016209904A1 (de) Verfahren und mikrofluidische Vorrichtung zum Verarbeiten einer Probe biologischen Materials
DE102014214173B4 (de) Verfahren zur selektiven größenfraktionierten Isolierung von Nukleinsäuren
EP3111220B1 (fr) Procédures pour diagnostics moléculaires pour enrichir un acide nucléique d'un échantillon biologique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FI FR GB IE IT LI NL SE

17Q First examination report despatched

Effective date: 20010806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020219